GMP transfer for an ADC drug substance program requires more than a finalized batch record. The receiving site needs to understand why the process was selected, which steps are sensitive, how samples should be handled and how analytical results should be interpreted. Without this knowledge, transfer can become a relearning exercise. Preparation begins during feasibility and process optimization. Teams should identify product-quality targets, main development risks, intended drug loading, impurity concerns, payload-linker stability and purification challenges. These early decisions shape the process knowledge that will later support transfer and deviation investigation. Analytical readiness is central. Methods used for early screening may be fit for purpose, but methods supporting GMP release, stability or submissions need stronger evidence of accuracy, reproducibility, robustness and transfer readiness. Analytical procedures should mature with the program rather than being rebuilt at the transfer stage. Scale-up work should also document mixing, addition behavior, filtration, UF/DF, hold times, intermediate stability and freeze-thaw performance. Establishing a scale-down model can help teams investigate future deviations and support process characterization. Draft control strategies should be linked to actual process knowledge, not created only for documentation. By the time transfer begins, the program should have aligned batch records, material specifications, sampling plans, reference standards, method transfer or validation plans, stability protocols and data-processing rules. These materials help the receiving team execute the process and understand what to do when unexpected results occur. ChemExpress supports ADC drug substance programs across payload-linker chemistry, antibody-related work, conjugation process development, analytical development, GMP manufacturing and CMC support. For sponsors, integrated support can reduce unnecessary handoffs and strengthen the knowledge package required for GMP transfer and lifecycle management.
ChemExpress Guest Post Content Package
For a drug substance CDMO article, the strongest contribution is to explain why project-specific evidence matters more than broad capability statements. Sponsors should not only ask whether a partner can make APIs or HPAPIs, but whether the proposed team, equipment, containment strategy and quality system match the actual chemistry and exposure-control profile of the molecule.
The article should also make clear that scale-up is not just a question of reactor volume. Crystallization behavior, heat transfer, mixing, impurity control, filtration, drying, cleaning limits and technology-transfer documentation can all affect timelines. Presenting these points gives the post stronger technical depth for API and small molecule manufacturing readers.
